Genetic Biomarker Development for TIGIT Inhibitor
Immune checkpoint inhibition (ICI) treatment presents improved clinical outcomes in melanoma and other solid tumors. However, the durability of treatment benefit, heterogeneity of ICI efficacy, and severe immune-related adverse events (irAEs) always result in disadvantages and constraints. In this case, the development of reliable and personalized biomarkers is efficient in predicting the least toxic outcomes and most benefits. Recently, growing interest has been concentrated on germline genetic factors to predict ICI efficacy, toxicity, and survival. Some studies have shown that host immune homeostasis is critical in ICI success determination, and germline genetic components are emerging determinants of host immune homeostasis. Till now, hundreds of genetic risk loci have been identified regarding autoimmune and inflammatory diseases.
